US sues Teva over claims of kickbacks for multiple sclerosis drug
The government says Teva used foundations as conduits to shield patients from a huge hike in the price of Copaxone, leading to hundreds of millions of dollars of false claims
18 August 2020 - 17:57
New York/Boston — The US government sued Teva Pharmaceutical on Tuesday, accusing the drugmaker of causing the submission of false claims to Medicare as a result of kickbacks it paid for its multiple sclerosis drug, Copaxone.
In a complaint filed with the US district court in Boston, the US department of justice said Teva violated the federal False Claims Act from 2006 to 2015 by paying two seemingly independent charitable foundations more than $300m to cover Medicare co-payment obligations of Copaxone patients...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.